Literature DB >> 6200416

The specificity of human liver membrane lipoprotein: studies with monoclonal antibodies.

H Murakami, J Kuriki, S Kakumu, K Fukui, N Sakamoto.   

Abstract

Hybrid cell lines which secreted antibodies to liver-specific membrane lipoprotein (LSP) were obtained by immunizing SMA and BALB/c mice with human LSP and fusing their splenocytes with the myeloma cell line P3-NSI/1-Ag4-1. The secretion of antibody to LSP (anti-LSP) was monitored by binding to a human hepatocellular carcinoma cell line, SK-Hep-1, which possesses surface membrane LSP, and to 125I-antimouse F(ab')2 antibody in radiobinding assay, and by reacting with 125I-LSP in double-antibody radioimmunoassay. From four separate cell fusions, seven secreting hybrids were cloned by dilutional techniques. Of these, four cell lines produced antibodies reacting with a wide variety of cells. The culture supernatants of the remaining three (6D6, 6G3 and 8F10) demonstrated the strongest binding activities against SK-Hep-1 among the various kinds of cell lines tested. However, binding with other cell lines, including renal cancer cells (SK-RC-6) and myeloid cell (HL-60) also occurred. Absorption test of ascitic fluids derived from 6D6 showed that ascitic fluids lost their capacity to bind to target SK-Hep-1 cells when absorbed with SK-Hep-1. Similarly absorption by SK-RC-6 and HL-60 removed almost all of the binding activity of ascitic fluids. Moreover, the binding activities of the ascitic fluids to SK-RC-6 and HL-60 were eliminated when absorbed with SK-RC-6, HL-60 and SK-Hep-1. The present study indicates that our LSP preparation contains nonspecific organ antigens, and although LSP exists on liver cell membrane, it is also found on the cell membrane of other organs albeit in less quantity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6200416     DOI: 10.1002/hep.1840040205

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  2 in total

1.  Enhancement of antibody production to hepatitis B surface antigen by anti-idiotypic antibody.

Authors:  S Kakumu; K Murase; A Tsubouchi; K Yoshioka; N Sakamoto
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

2.  Antibody to liver-specific lipoprotein in acute and chronic liver diseases. Its quantitative assay with monoclonal antibody, but without the use of liver-specific lipoprotein.

Authors:  S Kakumu; K Yoshioka; A Tsubouchi
Journal:  Gastroenterol Jpn       Date:  1985-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.